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Abstract
Background: Stents are commonly used to treat patients with coronary artery disease. However,
the quality of reporting internal and external validity data in published reports of randomised
controlled trials (RCTs) of stents has never been assessed.
The objective of our study was to evaluate the quality of reporting internal and external validity
data in published reports of RCTs assessing the stents for percutaneous coronary interventions.
Methods: A systematic literature review was conducted. Reports of RCTs assessing stents for
percutaneous coronary interventions indexed in MEDLINE and the Cochrane Central Register of
Controlled Trials and published between January 2003 and September 2008 were selected. A
standardized abstraction form was used to extract data. All analyses were adjusted for the effect
of clustering articles by journal.
Results: 132 articles were analyzed. The generation of the allocation sequence was adequate in
58.3% of the reports; treatment allocation was concealed in 34.8%. Adequate blinding was reported
in one-fifth of the reports. An intention-to-treat analysis was described in 79.5%. The main
outcome was a surrogate angiographic endpoint in 47.0%. The volume of interventions per center
was described in two reports. Operator expertise was described in five (3.8%) reports. The quality
of reporting was better in journals with high impact factors and in journals endorsing the
CONSORT statement.
Conclusion: The current reporting of results of RCTs testing stents needs to be improved to
allow readers to appraise the risk of bias and the applicability of the results.
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Background
In the past decade, stenting has become a routine treat-
ment for many patients with coronary artery disease [1].
Stent design has evolved through various iterations, with
the most important advance being the development of
drug-eluting stents (DESs). These advances were serially
evaluated in randomized clinical trials, often using reste-
nosis as an endpoint.
RCTs are widely accepted as the gold standard for the eval-
uation of new treatments [2]. The design, conduct, analy-
sis, and reporting of RCTs should follow specific
guidelines in order to provide valid results and avoid com-
mon pitfalls [3]. However, RCTs assessing stents face spe-
cific issues related to difficulties in blinding, the
complexity of the intervention, the influence of healthcare
providers, and centers' volume of care on treatment effect
[4-8]. For example, there are important variations and
evolutions in the techniques used for stenting, such as bal-
loon inflation pressure and use of intravascular ultra-
sound guidance, as well as in the type, dosing, and
duration of the pharmacological adjuvant therapy [9]. In
observational studies, the magnitude of differences in out-
comes related to these factors vastly exceeds those related
to use of new drugs or devices [7]. The reporting of these
data is therefore critical for an accurate appraisal of the
risk of bias and of the applicability of the results of RCTs
[10,11].
In the present study, we systematically appraised the
reporting of internal and external validity data in pub-
lished reports of RCTs assessing stents for percutaneous
coronary interventions (PCIs).
Methods
Search strategy and study selection
We identified all reports of RCTs published between Jan-
uary 1, 2003, and September 30, 2008, that assessed
stents. We searched MEDLINE using the PubMed interface
and the Cochrane Central Register of Controlled Trials
(issue 1, 2005) by using the terms implantable device OR
stents  [Mesh Terms] and cardiovascular disease [Mesh
Terms] with a limitation to clinical trials published in
English.
One author assessed the retrieved articles and screened the
titles and abstracts to identify relevant studies. We
included articles only if the study was identified as an
RCT, was published as a full-text article, and assessed
stents for PCI. We excluded case series, uncontrolled stud-
ies, articles published as abstracts only, editorials, news,
correspondence sections, articles not including a com-
plete description of the methods, and trials assessing
other implantable devices (e.g., pacemaker, defibrillator,
or cardiac valve) or stents in other vascular diseases.
Reports of RCTs assessing technical interventions or surgi-
cal procedures where the use of stents was not systemati-
cally required were also excluded. We screened articles for
duplicate publication (i.e., the same trial published with
results from different lengths of follow-up), and selected
only the original articles.
Data extraction
From a review of the relevant literature and according to
the CONSORT Statement guidelines [3], we generated a
standardized data collection form that was iterated among
the research team [5]. Before data extraction, as a calibra-
tion exercise, two members of the team (M.E., I.B.) inde-
pendently evaluated a separate set of 20 reports. A
meeting followed in which the ratings were reviewed and
disagreements were resolved by consensus. One reviewer
(M.E.) independently completed all the data extractions.
A second member of the team (I.B.) reviewed a random
sample of 25 articles as a quality assurance exercise. The
data abstraction form is available upon request [see addi-
tional file 1].
Trial characteristics
We collected data on trial characteristics: year of publica-
tion, funding source (public, manufacturer, or both),
number of centers, setting (primary, secondary, or aca-
demic), sample size, primary and secondary outcomes,
experimental treatment (DES, bare-metal stent [BMS],
polymer-coated stent, specific procedure of implantation
such as intravascular ultrasound-guided stenting that
could involve various categories of stents), and control
treatment (stent, specific procedure of implantation, sur-
gery, angioplasty, pharmacological treatment, or other).
We also checked whether statistical analyses were reported
to have been performed by a center independent of the
sponsor.
Study quality
The quality of reporting was assessed using CLEAR NPT –
a checklist specifically developed to evaluate the quality of
RCTs assessing nonpharmacological treatments [12].
These items focus on the reporting of the generation of
allocation sequence; allocation concealment; details of
the intervention administered in each group; operator
volume; blinding of patients, care providers and outcome
assessors; follow-up schedule; and intention to treat anal-
ysis. We also assessed whether the groups were described
as being similar at baseline regarding the main prognostic
factors and whether eligibility criteria were specified.
Outcomes
We checked whether the primary outcomes concerned a
clinical event such as death, cardiac death, myocardial inf-
arction, stroke, and revascularization, or an angiographicBMC Medical Research Methodology 2009, 9:24 http://www.biomedcentral.com/1471-2288/9/24
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surrogate outcome such as coronary restenosis or late
lumen loss.
Description of the intervention
We recorded reporting of details on the intended interven-
tions and on the procedural characteristics as they were
actually implemented. We checked which component of
the intervention was described: anesthesia management,
access site, equipment (e.g., wire, guide), stent (e.g.,
device description, manufacturer), the procedure (e.g., use
of predilatation balloon, number of inflations, duration
of inflations, number of implanted stents, number of
attempted lesions successfully treated, procedure dura-
tion), co-interventions and adjuvant pharmacotherapy
(either mandated or left to operator's discretion).
The reporting of a method to standardize the procedure, a
definition of successful procedure, and the reporting of
the rate of successful procedures was also recorded.
Description of care providers and centers
Data were recorded on the number of centers involved,
center volume for the experimental treatment and for sim-
ilar interventions, and the equipment in each center. We
checked whether the list of centers was provided along
with the number of patients treated in each. Additionally,
the following data on the care provider were retrieved:
reporting of selection criteria for operator (i.e., operators
reported as experienced, trained, or as having performed a
specific number of interventions, operators' years of prac-
tice or rates of complications); the number of operators
performing the experimental intervention; and the
number of patients treated by each operator.
Finally, we checked whether the clustering effect of
patients by healthcare providers and centers was taken
into account. In fact, in trials assessing nonpharmacolog-
ical treatments, observations for participants treated by
the same healthcare provider are not independent but
may be clustered in individually randomized trials. This
type of clustering is likely to affect the effect estimates
because it will inflate the standard error and reduce the
effective sample size, thus reducing the power of the trial
[13,14]. This type of clustering should consequently be
taken into account in sample size calculation and statisti-
cal analyses.
Statistical analysis
We reported descriptive statistics for quantitative varia-
bles: mean, standard deviation (SD), median (Q1 to Q3),
and minimum and maximum values. Categorical varia-
bles are described with frequencies and percentages. We
compared the quality of reporting (i.e., number of items
of CLEAR NPT adequately reported) and the sample size
according to the category of stent used (active stent [drug
eluting or polymer coated] versus BMS), the journal's
impact factor (<3 versus = 3), and whether the report fol-
lowed the CONSORT statement (reporting guidelines
comprising a checklist and flow diagram to help improve
the quality of reports of RCTs) in the framework of linear
models with mixed effects. For instance, in a first model,
the percentage of items with external validity was the
dependant variable, the category of stents was the fixed
effect on which F test was performed and journal was
entered in the model as a random effect. So, mean com-
parisons of percentage of items with external validity
between active and BMS stents were adjusted for the clus-
tering effect of articles by journals as been as recom-
mended (15).
All analyses were performed using the SAS system for Win-
dows, release 9.1 (SAS Institute, Cary, NC).
Results
Selected articles
We screened the titles and abstracts of 867 potentially eli-
gible reports; we examined the full text of 255 articles and
identified 132 studies that met our inclusion criteria [See
additional file 2].
The trial characteristics are reported in Table 1. Twenty
(15.2%) articles were published in a general medical jour-
nal. The median sample size was 388.6 (Q1 to Q3 109.5
to 496.5) patients. The source of funding was totally or
partially private in 56 (42.4%) reports and was not
reported in 57 (43.2%). The statistical analyses were man-
aged by independent centers in 26 (20.0%) reports.
Reporting on center and care provider
Over half (47.7%, n = 63) of the trials were multicenter
(Table 2). The median number of centers was 15.4 (Q1 to
Q3 1 to 22). The number of participating centers was not
reported or was unclear in 45 (34.1%) reports; the setting
was described in 19 reports. The authors provided a list of
participating centers in 45 (34.1%) reports. The volume of
interventions performed by each center was described in
only 2 (1.5%) reports.
Selection criteria for care providers were reported in five
(3.8%) reports. These criteria were related to the participa-
tion of "experienced" care providers, with no details on
the definition of "experienced". The number of care pro-
viders performing the intervention or the number of
patients treated by each care provider was never reported.
The clustering effect of participants by centers or by
healthcare providers was never taken into account.
Trial intervention
At least some details of the intended and actual interven-
tions for the experimental group were available in 121BMC Medical Research Methodology 2009, 9:24 http://www.biomedcentral.com/1471-2288/9/24
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(91.7%) and 98 (74.2%) reports, respectively (Table 2).
Anesthesia management was described in 1 (0.9%) report,
arterial access site in 21 (15.9%) reports, and data related
to the equipment used in 28 (21.2%) reports. Limited
data related to the procedural characteristics were
described in 98 (74.2%) reports. These data pertained
mainly to the number of stents implanted and to details
regarding the inflation balloon. In 49 (37.1%) reports, no
information was provided on the stent manufacturer. The
use of specific methods to standardize the procedure was
never reported. A definition of a successful intervention
was provided in 51 (38.9%) reports. The rate of successful
interventions was reported in 63 (48.5%) reports. Co-
interventions were described in 124 (93.9%) reports.
Outcomes
The primary outcome relied on surrogate angiographic
evaluation in almost half of the reports (Table 3). In 18
(13.6%) reports, angiography was a component of a com-
posite outcome and in 19 (14.4%) it was a secondary out-
come. Coronary angiograms were evaluated in 99 reports
and were reported as standardized in 41.2% (40 of 99).
Assessment of angiographic results was reported as cen-
tralized in 68.7% (68 of 99) of reports and blinded in
56.6% (56 of 99).
Trial quality
Trial quality according to the CLEAR-NPT checklist is
described in Table 4. For 8 out of 12 quality indexes in the
checklist, the overwhelming majority of reports failed to
Table 1: Reports' characteristics
n (%)
n = 132
Journal
General medical journal 20 (15.2)
Circulation 15 (11.4)
American Heart Journal 14 (10.6)
Catheter and Cardiovascular Intervention 18 (13.6)
Journal of the American College of Cardiology 17 (12.9)
American Journal of Cardiology 15 (11.4)
Other 33 (25.0)
Funding
Public funding 16 (12.1)
Manufacturer funding 49(37.1)
Both public and manufacturer funding 7 (5.3)
No funding 3 (2.3)
Not reported 57 (43.2)
Interventions
BMS 41 (31.1)
Polymer-coated stent 19 (14.4)
DES 64 (48.5)
Strategy of stent implantation 8 (6.1)
Comparisons (experimental intervention vs control arm)
DES vs BMS 35 (26.5)
DES vs another DES 19 (14.4)
DES vs same DES but with a different dosage 5 (3.8)
DES vs balloon angioplasty 6 (4.5)
DES vs polymer-coated stent 3 (2.3)
DES vs surgery 1 (0.8)
Polymer-coated stent vs BMS 13 (9.8)
Polymer-coated stent vs angioplasty 3 (2.3)
BMS vs another BMS 13 (9.8)
BMS vs angioplasty 10 (7.6)
BMS vs surgery 9 (6.8)
BMS vs a strategy of stent implantation 6 (6.8)
Strategy of stent implantation vs another strategy of stent implantation 4 (3.0)
Strategy of stent implantation vs angioplasty 5 (3.8)
BMS = bare-metal stent
DES = drug-eluting stentBMC Medical Research Methodology 2009, 9:24 http://www.biomedcentral.com/1471-2288/9/24
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Table 2: Reporting of the different components of the intervention intended or actually administered
Reporting of n = 132 (%)
Intervention as intended 121 (91.7)
Intervention as actually administered 98 (74.2)
Component of the intervention described
Anesthesia management 1 (0.9)
Access site (i.e. transfemoral access site) 21 (15.9)
Data on equipment (i.e., guide catheters, wires) 28 (21.2)
Data on stent 99 (75.0)
Left to operator's discretion 5 (3.8)
Description of the device (i.e., length, component) 74 (56.1)
Manufacturer 83 (62.9)
Procedural characteristics 98 (74.2)
Number of stents implanted 73 (55.3)
Use of dilatation balloon 59 (44.7)
Number of inflations 9 (6.8)
Duration of inflation 12(9.1)
Number attempted and successfully treated 12 (9.1)
Procedure duration 8 (6.1)
Co-interventions 124 (93.9)
Setting
Secondary setting 1 (0.8)
Tertiary or academic setting 18 (13.6)
Not reported 113 (85.6)
Center
Single 24 (18.2)
Multicentre 63 (47.7)
Not reported or unclear 45 (34.1)
Centers
Stratification on centers 10 (7.6)
Number of centers (median, Q1 to Q3) 15.4 (1–22)
List of participating centers 45 (34.1)
Center volume reported 2 (1.5)
Source of equipment reported 1 (0.8)
Specific equipment required 0
Operators
Selection criteria for operators 5 (3.8)
Number of operators (median, Q1 to Q3) 5.5 (5–6)
Number of patients treated by each operator 0
Clustering effect taken into account 0
Table 3: Primary outcomes reported in randomized controlled trials assessing stents
Primary Outcome
N (%)
N = 132
Angiographic evaluation (e.g., coronary restenosis) 62 (47.0)
Major cardiac events and repeat revascularization 25 (18.9)
Major cardiac events, repeat revascularization and angiographic evaluation 8 (6.1)
Repeat revascularization 7 (5.3)
Major cardiac events 8 (6.1)
Other 22 (16.7)BMC Medical Research Methodology 2009, 9:24 http://www.biomedcentral.com/1471-2288/9/24
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provide appropriate information. The generation of allo-
cation sequence was adequate in 31 (38.8%) reports;
treatment allocation was concealed in 21 (26.3%).
Patients, care providers, and outcome assessors were ade-
quately blinded in approximately one-fifth of the reports.
An intention to treat analysis was described in 56 (70.0%)
reports. Patient eligibility criteria were specified in all
reports.
Factors associated with good reporting
The quality, measured by the median [Q1 to Q3] number
of items on the CLEAR NPT checklist that were adequately
reported, was higher for trials published in journals with
a high impact factor versus those in a lower impact factor
journal (4.0 [3.0 to 7.0] versus 3.0 [1.0 to 5.0]; p = 0.007)
and in journals endorsing the CONSORT statement versus
those not (7.0 [4.0 to 8.0] versus 4.0 [2.0 to 6.0]; p =
0.002), but was statistically different for active stent vs
BMS (p < 0.0001).
The mean (SD) sample size was higher in journals with a
high impact factor (469.2 [427.7] vs 251.8 [328.1]; p =
0.004) and when published in journals endorsing the
CONSORT statement 750.6 [538.9] vs 335.1 [355.6]; p =
0.002), but was not statistically different for active stent vs
BMS.
Discussion
This study evaluated the reporting of the results of RCTs
assessing stents for PCIs published between January 2003
and September 2008. Several studies have assessed the
methodological quality of a broad range of reports of ran-
domized trials in several areas of health care [15-17]. Con-
cerns have been raised regarding the quality of trials
assessing DESs [18]. However, to the best of our knowl-
edge, no study has systematically assessed the quality of
reporting of trials performed in this field.
Although some important data related to the description
of the intervention intended and actually administered,
and co-interventions provided, were adequately reported,
our results highlight poor reporting of data related to the
internal validity (i.e., unbiased estimates of treatment
effect) and external validity (i.e., applicability of the
results) of the trials.
The assessment of internal validity highlights important
pitfalls: treatment allocation was concealed in only 34.8%
of the reports; blinding of outcome assessors was reported
in approximately one-third of the reports; and intention-
to-treat analysis was reported in 79.5% of the studies. Lack
of reporting of these data is associated with an increasing
risk of bias, in the form of exaggerated and possibility spu-
rious estimates of treatment effects [19].
The choice of the primary outcome in these trials also
raises some concern. In about half of the reports, the main
outcomes relied on angiographic evaluation such as coro-
nary restenosis or late lumen loss. These outcomes are sur-
rogates of clinical events and their relevance may be
questionable. Marked increases in late lumen loss (>four-
fold difference) are not necessarily associated with sub-
stantial differences in major cardiac events, and thus the
validity of these surrogate endpoints is questioned
[18,20]. Further, clinicians may extrapolate these results
and consider the results of the trial equivalent to clinically
relevant efficacy.
In about 20% of the reports, the main outcome was a
composite associating major adverse cardiac events and
revascularization. Clinical trials often use composite end-
Table 4: Assessment of the quality of selected randomized controlled trials using the CLEAR NPT checklist
Yes
n (%)
No
n (%)
Unclear
n (%)
Adequate generation of allocation of sequence 77 (58.3) 0 55(41.7)
Concealment of treatment allocation 46 (34.8) 0 86 (65.2)
Details of intervention used in each group available 125 (94.7) 0 7 (5.3)
Care providers' experience or skill in each arm appropriate 3 (2.3) 0 129 (97.7)
Participants adequately blinded 23 (17.4) 63 (47.7) 46 (34.9)
Care providers adequately blinded 16 (12.1) 74 (56.1) 42 (31.8)
If patients and/or care providers were not adequately blinded:
All other treatments and care were the same in each group 97 (73.5) 5 (3.8) 9 (6.8)
Withdrawals and lost to follow-up were the same in each group 46 (34.8) 6 (4.5) 61 (46.2)
Outcome assessors adequately blinded to assess the primary outcomes 39 (29.5) 44 (33.3) 49 (37.1)
If outcome assessors were not adequately blinded:
Specific methods were used to avoid ascertainment bias 2 (1.5) 13 (9.8) 76 (57.6)
Follow-up schedule was the same in each group 105 (79.5) 2 (1.5) 23 (17.4)
Main outcomes analyzed according to the intention-to-treat principle 105 (79.5) 17 (12.9) 10 (7.6)BMC Medical Research Methodology 2009, 9:24 http://www.biomedcentral.com/1471-2288/9/24
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points to reduce sample size requirements. However, such
measures may prove challenging for the interpretation of
results, particularly if the component endpoints are of
widely differing importance to patients and the magni-
tude of effect differs markedly across components [21-23].
Both European Society of Cardiology [24] and American
College of Cardiology/American Heart Association/Soci-
ety for Cardiovascular Angiography and Interventions
[24] guidelines indicate that elective PCIs should be per-
formed by operators with acceptable annual volume at
high-volume centers with on-site cardiac surgery facilities
[25]. In fact, there is abundant evidence that hospitals
with a larger volume of activity tend to have better out-
comes and that care providers' volume of work is also a
determinant for outcomes following revascularization
[4,25-29]. The organization of the hospital (e.g., on-site
cardiologist, activation of the catheterization laboratory
by emergency physician or prehospital personnel) also
impacts outcomes [30]. This is even more marked in the
context of acute coronary syndromes [7,31]. Surprisingly,
data related to the number and expertise of the centers
and operators involved in the trial were lacking, and the
potential impact of the volume was never adequately
reported or taken into account in the planning (stratifica-
tion) or the analyses. Consequently, readers are unable to
appraise the reports adequately. In fact, an intervention
might be found to be safe and effective in an RCT per-
formed in high-volume centers by high-volume operators,
but it could not be assumed that these results put into
practice in low-volume centers would be identical. Une-
qual expertise of healthcare providers in each arm could
also bias treatment-effect estimates [32]. Likewise, proce-
dure characteristics (inflation number, duration or maxi-
mal pressure) and details on the surrounding
management, such as data on equipment, access site,
anaesthesia management or adjuvant therapy, were fre-
quently lacking.
Finally, in trials assessing stents, operators are integral
parts of the intervention, and observations on participants
treated by the same operator may be somewhat similar or
clustered [13]. This clustering will inflate standard error
and reduce trial power. Furthermore, in these settings, the
assumption of independence of data is violated, which
means that standard statistical analyses are invalid and
may give misleading conclusions. However, this issue was
never addressed in the statistical analyses or the sample
size calculations [14].
Study limitations
Our search strategy and selection criteria for the reports
assessed might not be comprehensive. In fact, many trials
evaluating PCIs also use stents, and these were not
included since stents were not the experimental therapy.
However, our aim was to focus only on trials specifically
assessing stents and our panel is representative of the pub-
lished trials. Our analysis is based on reports of RCTs
rather than on the trials themselves. Clearly, failure to
report is not equivalent to failure to actually carry out the
procedure or to implement adequate methods [20]. Con-
sequently, poor or insufficient reporting is not necessarily
equivalent to low quality trials. However, the published
report is the only document available for readers to
appraise the quality of trials, particularly in meta-analyses
and systematic reviews. Empirical evidence of bias also
relies mainly on the reporting of trials [19,33].
Conclusion
This study highlights the inadequate reporting of contem-
porary trials involving stents. Such inadequate reporting is
particularly problematic, as the technical advances tested
are often rapidly implemented in clinical practice without
the possibility for an adequate critical assessment of the
methods used to test them.
It is desirable to increase the awareness of interventional
cardiology trialists regarding checklists and guidelines for
reporting trial quality such as the CONSORT Statements.
With access to electronic reporting, detailed reporting of
methods and quality assurance is easy to implement, and
would substantially increase the quality of reporting. This
would be valuable to interventional cardiologists and to
the broader cardiology community for proper interpreta-
tion of the evidence regarding the use of stents in PCI.
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